Principia Biopharma (PRNB) announced a mutual agreement with AbbVie (ABBV) to end their collaboration aimed at developing oral immunoproteasome inhibitors and for Principia to reacquire the rights to the program. The two companies have agreed to conclude the collaboration effective March.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.